MP Materials to Participate in Upcoming Conferences
MP Materials to Participate in Upcoming Conferences
MP Materials Corp. (NYSE: MP) today announced that James Litinsky, Founder, Chairman, and Chief Executive Officer, will participate in the following conferences:
The Jefferies Industrials Conference on Wednesday, September 4, 2024, at 1:20 p.m. Eastern Time.
Morgan Stanley 12th Annual Laguna Conference on Wednesday, September 11, 2024, at 2:05 p.m. Eastern Time.
A live webcast and replay will be available at https://investors.mpmaterials.com/.
About MP Materials
MP Materials (NYSE: MP) produces specialty materials that are vital inputs for electrification and other advanced technologies. MP’s Mountain Pass facility is America’s only scaled rare earth production source. The company is currently expanding its manufacturing operations downstream to provide a full supply chain solution from materials to magnetics. More information is available at https://mpmaterials.com/.
Join the MP Materials community on Twitter, YouTube, Instagram and LinkedIn.
Investors:
ir@mpmaterials.com
Media:
Matt Sloustcher
media@mpmaterials.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20240828778999/en/
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks